Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cell Metab. 2009 May;9(5):407-16. doi: 10.1016/j.cmet.2009.03.012.

AMPK: an emerging drug target for diabetes and the metabolic syndrome.

Author information

  • 1Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07065, USA. bei_zhang@merck.com

Abstract

Adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) is a key player in regulating energy metabolism, placing it at the center stage in studies of diabetes and related metabolic diseases. Expressed in key metabolically relevant organs, AMPK is activated in response to a variety of stimuli, including cellular stress, exercise, and a wide range of hormones and agents that exert impacts on cellular metabolism. Genetic and pharmacological studies demonstrate that AMPK is required for maintaining glucose homeostasis. Activation of AMPK by pharmacological agents presents a unique challenge, given the complexity of the biology, but holds a considerable potential to reverse the metabolic abnormalities associated with type 2 diabetes.

PMID:
19416711
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk